ISSN: 2278-0238

薬学および生命科学における研究開発の国際ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Review: Recent Perspectives in Ocular Drug Delivery

Mr. Rahul S Khaire

The delivery of drugs to the eye has been a major challenge for pharmacologists due to the unique anatomy and physiology of the eye. Static barriers (various layers of the cornea, sclera, and retina, including aqueous and bloodretinal barriers), dynamic barriers (choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution), and drip pumps. especially in the rear segment. The identification of impulse transporters on different ocular tissues and the design of a transporter-targeted parenteral drug delivery have gained momentum in recent years. In parallel, colloidal dosage forms such as nanoparticles, nanocells, liposomes, and micro emulsions have been extensively studied to overcome various static and dynamic barriers. Novel drug delivery strategies such as bioadhesive gels and fibrin glues have been developed to maintain drug levels at the target site. The development of non-invasive continuous drug delivery systems and research into the feasibility of local use for post-drug delivery could greatly improve drug delivery in the years to come. Recent developments in the field of ophthalmic drug delivery promise significant improvements in overcoming the challenges of various diseases of the anterior and posterior segments of the eye. A better understanding of the nature of ocular diseases, barriers, and factors affecting in vivo performance would significantly advance the development of new delivery systems. The current momentum in the invention of new drug delivery systems promises greatly improved therapies for the treatment of vision disorders.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。